Table 5. Characteristics of hospitalized neonates without COVID-19.
| Patient | 1 | 2 | 3 | 4 | 6 | 7 | 8 | 11 | 13 | 14 | 15 | 16 | 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days from mother diagnosed, days | 7 | 7 | 1 | -2 | -2 | 0 | 0 | -2 | -1 | 1 | 0 | 0 | 0 |
| Sex | Female | Female | Female | Female | Male | Female | Male | Male | Male | Male | Female | Female | Male |
| Gestational age, weeks | 37+1 | 37+6 | 35+6 | 35+5 | 39+5 | 39+4 | 39+0 | 38+4 | 37+2 | 40+1 | 37+2 | 37+2 | 38+1 |
| Birthweight, g | 2,890 | 3,400 | 2,830 | 2,300 | 3,450 | 2,650 | 3,000 | 2,650 | 2,900 | 3,830 | 2,350 | 2,620 | 2,930 |
| AGA | AGA | AGA | AGA | AGA | AGA | SGA | AGA | SGA | AGA | AGA | SGA | AGA | AGA |
| Apgar score at 1 minute | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 7 | 10 | 10 | 10 | 10 | 10 |
| Apgar score at 5 minutes | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Congenital anomaly | No | No | No | No | No | No | PDA | No | No | No | No | No | PDA |
| Fever | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Other symptoms | Occasional cough | NEC (bloody stools, Day 4) | No | No | No | No | No | Mild birth asphyxia | No | NEC (bloody stools, Day 4) | NEC (repeated vomiting and bloating, Day 2) | No | No |
| Throat swab | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) |
| Anal swab | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) |
| Chest X-ray or CT after birth | Patchy obscure shadow in the left lower lung field | Scattered patchy shadows in bilateral lung fields | Scattered patchy shadows in bilateral lung fields | Scattered patchy shadows in bilateral lung fields | Focal patchy consolidation is infiltrated around the left lower bronchial and paramediastinal emphysema | Scattered patchy shadows in bilateral lung fields | Focal GGO located in the medial basal segment of right lower lobe | Increased bilateral lung markings | Multifocal patchy GGOs bilaterally and focal consolidation located in the medial basal segment of right lower lobe | Pneumonia, bilateral thickened interlobular fissure | Decreasing changes of pulmonary lucency presenting as GGO in bilateral lower lobes and focal consolidation around the left lower bronchial | Multifocal consolidations located in the peripheral region of bilateral lower lobes | Diffuse GGO with multifocal consolidations located in bilateral lower lobes |
| Treatment | Sulbactam-Cefoperazone | Meropenem (for NEC) | Symptomatic treatment | Symptomatic treatment | Ceftazidime | Amoxicillin-Clavulanate potassium | Interferon inhalation | Amoxicillin-Clavulanate potassium | Interferon inhalation | Ceftazidime | Interferon inhalation, Ceftazidime, NEC treatment | Interferon inhalation, Ceftazidime | Interferon inhalation, Amoxicillin-Clavulanate potassium |
| NICU stay, days | 11 | 14 | 11 | 13 | 11 | 7 | 11 | 8 | 15 | 16 | 30 | 14 | 15 |
| Hospitalization stay, days | 11 | 17 | 11 | 28 | 14 | 7 | 14 | 26 | 15 | 16 | 30 | 14 | 15 |
| X-ray or CT before discharge | No abnormalities | Slightly increasing lung markings | Slightly increasing lung markings | Slightly increasing lung markings | No abnormalities | Slightly increasing lung markings | No abnormalities | Increased bilateral lung markings (Day 41) | No abnormalities | No abnormalities | Scattered patchy blurry shadows | No abnormalities | Pulmonary lesions are almost resolved |
| Discharge diagnosis | Hyperbilirubinemia | NEC | Hyperbilirubinemia | Premature infant | Hyperbilirubinemia | Myocardial damage | PDA | HIE | Hyperbilirubinemia | NEC | NEC | Hyperbilirubinemia | PDA |
(–), negative; (+), positive; those who tested negative for multiple times also showed (–).
AGA, appropriate for gestational age; COVID-19, coronavirus disease 2019; CT, computed tomography; GGO, ground-glass opacity; HIE, hypoxic-ischemic encephalopathy; NEC, neonatal necrotizing enterocolitis; PDA, patent ductus arteriosus; SGA, small for gestational age.